An experimental drug for prevention of chronic migraine headaches from Amgen Inc met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo, the company said on Wednesday. The biotech drug, erenumab, which is being co-developed with Swiss drugmaker Novartis, was tested at two doses in a…